AVEANNA HEALTHCARE ($NASDAQ:AVAH) announced their financial results for the third quarter of the fiscal year 2023 (ending on September 30 2023) on November 9 2023. Total revenue for the quarter was USD 478.0 million, an increase of 7.9% compared to the same period in the previous fiscal year. Unfortunately, net income reported a decrease from 24.3 million in Q3 FY2022 to -102.4 million.
With the release of its financial results, the stock opened at $1.5 and closed at $1.5, representing a 2.0% increase from the previous closing price of $1.5. Overall, AVEANNA HEALTHCARE delivered solid financial performance in the third quarter of fiscal year 2023, with the stock closing up by 2.0%. Investors will be closely watching the company’s progress in the fourth quarter as it continues to strive for further success. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Aveanna Healthcare. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aveanna Healthcare. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aveanna Healthcare. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Aveanna Healthcare are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Aveanna Healthcare Stock Fair Value
At GoodWhale, we conducted an analysis of AVEANNA HEALTHCARE‘s wellbeing. We used our proprietary Valuation Line to calculate the intrinsic value of AVEANNA HEALTHCARE’s share at approximately $4.3. Currently, AVEANNA HEALTHCARE’s stock is traded at $1.5, which presents an undervaluation of 65.3%. This significant gap between the market price and intrinsic value is an opportunity to invest in AVEANNA HEALTHCARE, as long-term investors may benefit from such a discount. More…
Star Chart Analysis
The competitive landscape in the home healthcare services industry is heating up, with Aveanna Healthcare Holdings Inc taking on Amedisys Inc, InnovAge Holding Corp, and National Healthcare Corp. All four companies are vying for a piece of the pie in an industry that is expected to grow significantly in the coming years. While each company has its own strengths and weaknesses, it is clear that Aveanna is in a strong position to compete against its rivals.
Amedisys Inc is a home health care company with a market cap of 3.17B as of 2022. The company has a Return on Equity of 11.56%. Amedisys Inc provides home health and hospice services to patients in the United States. The company offers a variety of services, including skilled nursing, physical therapy, occupational therapy, speech therapy, and home health aides. Amedisys Inc also provides palliative care and hospice services.
– InnovAge Holding Corp ($NASDAQ:INNV)
InnovAge Holding Corp is a provider of senior services in the United States. The company has a market cap of 829.66M as of 2022 and a return on equity of -0.87%. The company offers a variety of services to seniors, including home health care, transportation, and meals. The company also has a number of programs designed to help seniors stay healthy and independent, such as exercise and wellness programs.
– National Healthcare Corp ($NYSEAM:NHC)
National Healthcare Corporation is a real estate investment trust that invests in senior housing and healthcare properties. As of December 31, 2020, the company owned and operated 245 senior housing and healthcare properties in 29 states and Puerto Rico.
AVEANNA HEALTHCARE recently reported its fiscal year 2023 third quarter earnings results, with total revenue increasing 7.9% to USD 478.0 million, but reported net income showing a decrease of USD 102.4 million from the same period last year. Investors should take note of the company’s impressive revenue growth, but also consider the decline in net income when evaluating the stock. Going forward, investors should continue to monitor the company’s financial performance and operational efficiency to assess the potential for long-term growth and profitability.